Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 10/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 9/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 5/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.69 |
| ▸ | QPCT | Q16769 | 1/20 | 0.69 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.69 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.69 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024261 | 0.92 | CYP11B1 (0.84) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| Oxalic Acid SCHEMBL11534580 | 0.90 | CYP19A1 (0.81) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| Hydrochloric Acid SCHEMBL1775141 | 0.90 | CYP11B1 (0.81) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2926364 | 0.87 | CYP19A1 (0.78) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2930261 | 0.87 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL11701053 | 0.86 | CYP11B1 (0.73) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2529997 | 0.86 | CYP11B1 (0.86) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL6057476 | 0.86 | CYP11B1 (0.75) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2729830 | 0.83 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2393534 | 0.82 | CYP11B1 (0.70) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107216315-A | Flavones glyoxaline compound and preparation method thereof | 盐城师范学院 | 2017-09-29 | — | — | CN | claimed |
| CN-104672145-B | Glycalpyramide derivative and application thereof in preparing anticoccidial drug | 广州英赛特生物技术有限公司 | 2017-04-12 | — | — | CN | claimed |
| US-20250214978-A1 | AT2R AGONIST | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4506345-A1 | AT2R AGONIST | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023235376-A1 | PROCESS FOR PREPARING 1-(4-CHLOROBENZYL)-1H-IMIDAZOLE-4,5-DICARBOXAMIDE | ZOETIS SERVICES LLC (US) | 2023-12-07 | — | — | WO | disclosed |
| CN-116891464-A | AT2R agonist | 武汉人福创新药物研发中心有限公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2023193733-A1 | AT2R AGONIST | 武汉人福创新药物研发中心有限公司 | 2023-10-12 | — | — | WO | disclosed |
| CN-107216315-A | Flavones glyoxaline compound and preparation method thereof | 盐城师范学院 | 2017-09-29 | — | — | CN | disclosed |
| CN-106692138-A | Application of N-benzylimidamide derivative as polymyxin antibiotic synergist | 广州英赛特生物技术有限公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-104672145-B | Glycalpyramide derivative and application thereof in preparing anticoccidial drug | 广州英赛特生物技术有限公司 | 2017-04-12 | — | — | CN | disclosed |
| US-8906943-B2 | Synthetic compounds and methods to decrease nicotine self-administration | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2014-12-09 | — | — | US | disclosed |
| US-20120196905-A1 | SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-08-02 | — | — | US | disclosed |
| WO-2012019093-A1 | SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-02-09 | — | — | WO | disclosed |
| CN-102119240-A | Surface treating agent for copper or copper alloy and use thereof | SHIKOKU CHEM | 2011-07-06 | — | — | CN | disclosed |
| US-5100890-A | Antidepressants, Fungicides | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-03-31 | — | — | US | disclosed |
| EP-0218118-B1 | ARYLMETHYL AZOLES AND THEIR SALTS, METHOD FOR THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-09-18 | — | — | EP | disclosed |
| US-5023357-A | Arylmethylazole preparation processes | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-06-11 | — | — | US | disclosed |
| US-4876354-A | FUNGICIDES, ANTIDEPRESSANTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-10-24 | — | — | US | disclosed |
| EP-0218118-A1 | Arylmethyl azoles and their salts, method for their preparation, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-04-15 | — | — | EP | disclosed |
| US-4152441-A | Analgesic imidazolemethanols | GIST-BROCADES N.V. (NL) | 1979-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214978-A1 | AT2R AGONIST | AGTR1, AGTR2, AVPR2 | CYP11B1 113/4885CYP11B2 88/4885CYP19A1 2203/4885 |
| US-20120196905-A1 | SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION | SLC6A3, NNT, SLC6A2 | CYP11B1 1125/4885CYP11B2 1186/4885CYP19A1 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.